Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Avid Bioservices Inc is a biotechnology business based in the US. Avid Bioservices shares (CDMO) are listed on the NASDAQ and all prices are listed in US Dollars. Avid Bioservices employs 252 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $17.78 |
|---|---|
| 52-week range | $13.35 - $34.51 |
| 50-day moving average | $27.55 |
| 200-day moving average | $24.65 |
| Wall St. target price | $32.67 |
| PE ratio | 133.8235 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $0.14 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $17.78 from 2022-01-25
| 1 week (2022-01-15) | N/A |
|---|---|
| 1 month (2021-12-22) | N/A |
| 3 months (2021-10-22) | N/A |
| 6 months (2021-07-26) | -29.14% |
| 1 year (2021-01-26) | 26.19% |
|---|---|
| 2 years (2020-01-24) | 157.68% |
| 3 years (2019-01-25) | 342.29% |
| 5 years (2017-01-26) | 5,779.63% |
Valuing Avid Bioservices stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Avid Bioservices's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Avid Bioservices's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 134x. In other words, Avid Bioservices shares trade at around 134x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Avid Bioservices's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $20.2 million.
The EBITDA is a measure of a Avid Bioservices's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $106.3 million |
|---|---|
| Operating margin TTM | 15.39% |
| Gross profit TTM | $29.3 million |
| Return on assets TTM | 4.92% |
| Return on equity TTM | 27.91% |
| Profit margin | 13.2% |
| Book value | $0.83 |
| Market capitalisation | $1.1 billion |
TTM: trailing 12 months
We're not expecting Avid Bioservices to pay a dividend over the next 12 months.
Avid Bioservices's shares were split on a 1:7 basis on 9 July 2017. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Avid Bioservices shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Avid Bioservices shares which in turn could have impacted Avid Bioservices's share price.
Over the last 12 months, Avid Bioservices's shares have ranged in value from as little as $13.35 up to $34.51. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Avid Bioservices's is 2.2955. This would suggest that Avid Bioservices's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Avid Bioservices, Inc. , a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. It serves biotechnology and pharmaceutical companies. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc.
Steps to owning and managing CORZ, with 24-hour and historical pricing before you buy.
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.